Sevelamer (RenaGel)

A polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease.

Also Known As:

RenaGel; GT335-012; Sevelamer Carbonate; Sevelamer Hydrochloride; Carbonate, Sevelamer; GT335 012; GT335012; Hydrochloride, Sevelamer; poly(allylamine-co-N,N'-diallyl-1,3-diamino-2-hydroxypropane)

Networked: 444 relevant articles (71 outcomes, 115 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Polyamines: 3918
    - Sevelamer: 444

Experts

1.	Ketteler, Markus: 13 articles (01/2021 - 08/2004)
2.	Burke, Steven K: 12 articles (12/2008 - 07/2002)
3.	Chertow, Glenn M: 11 articles (10/2021 - 07/2002)
4.	Cozzolino, Mario: 9 articles (01/2021 - 09/2002)
5.	Floege, Jürgen: 9 articles (06/2020 - 08/2004)
6.	Raggi, Paolo: 8 articles (10/2016 - 07/2002)
7.	Bellasi, Antonio: 7 articles (01/2021 - 10/2013)
8.	Rastogi, Anjay: 7 articles (01/2020 - 12/2013)
9.	Sprague, Stuart M: 7 articles (01/2020 - 12/2007)
10.	Nagano, Nobuo: 7 articles (03/2006 - 06/2003)

Related Diseases

1.	Hyperphosphatemia 10/01/2018 - "SFOH is an efficacious and well-tolerated treatment for hyperphosphatemia in AA dialysis patients, with a lower pill burden and an improved adherence rate vs. sevelamer. " 12/01/2007 - "Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. " 12/01/2023 - "The safety and efficacy of sevelamer as a treatment for hyperphosphatemia in CKD patients were then examined through a meta-analysis, with the primary patient-level outcomes of interest in this analysis being all-cause mortality and the incidence of gastrointestinal adverse effects. " 01/01/2023 - "This finding further consolidates the efficacy of sevelamer in treating hyperphosphatemia with TLS. " 04/01/2023 - "This study assessed the efficacy and safety of sevelamer carbonate in Chinese nondialysis CKD patients with hyperphosphatemia. "
2.	Hypercalcemia (Milk Alkali Syndrome) 01/01/2015 - "This meta-analysis suggests that sevelamer benefits dialysis patients in terms of CACS, ACS and hypercalcemia." 05/01/2014 - "However, sevelamer hydrochloride seems to be superior among all with lowering incidence of hypercalcemia. " 06/01/2004 - "The incidence of hypercalcemia for sevelamer was not different from the incidence of hypercalcemia during the washout period. " 03/01/2003 - "The near future use of sevelamer hydrochloride under development which does not cause hypercalcemia will be attained at such a case. " 04/01/1999 - "The incidence of hypercalcemia for sevelamer was not different from the incidence of hypercalcemia during the washout period. "
3.	Vascular Calcification 10/01/2007 - "These data suggest that sevelamer treatment is associated with an improvement in aortic stiffness in HD patients, but it does not seem to affect serum levels of inhibitors of vascular calcification." 03/01/2017 - "Meta-analyses report reduced hypercalcaemia for non-CBBs versus CBBs, and compared with CBBs sevelamer has been reported to significantly reduce vascular calcification progression and, in some but not all studies, overall mortality. " 01/01/2018 - "Sevelamer, appear to have profiles that would lead to pleiotropic effects and reduced progression of vascular calcification, and the main adverse events seen with these agents are gastrointestinal. " 11/01/2016 - "Treatment with PPi (30 or 120 µmol/kg/day), sevelamer carbonate (1500 mg/kg/day) or vehicle was started at the time point at which vascular calcification was present and continued for 3 weeks. " 06/01/2016 - "This effect could contribute to the still controversial superiority of sevelamer in preventing vascular calcifications."
4.	Chronic Renal Insufficiency 12/04/2023 - "This study aimed to investigate the role of sevelamer in GI injury among chronic kidney disease (CKD) patients. " 01/01/2013 - "Additional studies are needed to evaluate the potential effects of sevelamer treatment on nutritional status in chronic kidney disease (CKD) patients with elevated ET." 04/01/2009 - "The aim of study was the estimation of efficacy and safety of sevelamer treatment in children with chronic kidney disease with resistant hyperphsphatemia. " 07/01/2008 - "This study investigated the ability of sevelamer carbonate to control serum phosphorous in hyperphosphatemic patients who had chronic kidney disease and were not on dialysis. " 12/04/2023 - "Patterns of gastrointestinal injury in patients with chronic kidney disease: Comparison of cases with and without sevelamer crystals."
5.	Chronic Kidney Failure (Chronic Renal Failure) 12/01/2013 - "Endothelial effects of sevelamer may contribute mechanistically to the improved survival observed in some studies of CKD and ESRD patients." 01/01/2019 - "Sevelamer hydrochloride suppresses proliferation of parathyroid cells during the early phase of chronic renal failure in rats." 02/01/2016 - "Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease." 12/01/2013 - "This review discusses recent exploratory evidence for pleiotropic effects of sevelamer on endothelial function in CKD or ESRD. " 12/01/2013 - "The present cross-sectional study is nested in the Sevelamer hydrochloride and ultrasound-measured femoral and carotid intima media thickness progression in end-stage renal disease (SUMMER) clinical trial. "

Related Drugs and Biologics

1.	Phosphates (Orthophosphate)
2.	Calcium
3.	Sevelamer (RenaGel)
4.	Calcium Carbonate (Limestone)
5.	lanthanum carbonate (Fosrenol)
6.	Lipids
7.	Phosphorus (Red Phosphorus)
8.	Aluminum
9.	calcium acetate (Phoslo)
10.	Vitamin D

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics
3.	Peritoneal Dialysis
4.	Aftercare (After-Treatment)
5.	Drug-Eluting Stents